Aspects of driving after hypnotic therapy with particular reference to temazepam.
In a double-blind study, 32 outpatients with sleep disorders received oral doses of temazepam 20 mg (n = 16) or flunitrazepam 2 mg (n = 16) once a night for 7 days. On the morning after the first and seventh doses, patients completed psychomotor tests and a real driving test on the road over a 25 km course. The road test included a 1 km straight stretch driven at constant speed. In the car, various parameters were automatically recorded every second for approximately 60 minutes. These included angular velocity of steering, lateral acceleration and velocity. An optimization quotient, a measure of the efficiency of information processing in the driver-vehicle-road interaction, was derived from these parameters. An observer recorded driving performance by scoring standardized tasks. After a single dose of temazepam, the improvement in driver performance as shown by a decreased optimization quotient was significantly different to the deterioration seen after flunitrazepam (p less than 0.05). After the seventh dose, this trend was still apparent but was not statistically significant. After both one and seven doses, the angular velocity of steering was significantly decreased in the temazepam group compared with an increase after flunitrazepam (p less than 0.001). Over the straight, this deterioration in steering ability in the flunitrazepam group was apparent after one dose and reached statistical significance compared with temazepam after seven doses (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D001143:Arousal / Q000187:drug effects*; D001288:Attention / Q000187:drug effects; D001334:Automobile Driving; D005260:Female; D005445:Flunitrazepam / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013693:Temazepam / Q000009:adverse effects* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D005445:Flunitrazepam; D013693:Temazepam